New research finds that Crohn’s and colitis patients start developing depression and anxiety years before they are diagnosed. The gut-brain connection begins earlier than anyone realized

The mental health burden of inflammatory bowel disease has been documented for decades. People living with Crohn’s disease or ulcerative colitis experience depression and anxiety at rates roughly one and a half to two times higher than the general population. The explanation has always seemed straightforward: a lifelong condition causing unpredictable pain, frequent hospitalizations, dietary restrictions, and social disruption naturally takes a toll on mental health. The gut disease comes first, the psychiatric consequences follow.

A new nationwide study has found that the sequence is wrong.

Published in Clinical Gastroenterology and Hepatology, the study tracked 43,862 Swedish patients diagnosed with inflammatory bowel disease between 2007 and 2023. Each IBD patient was matched against up to four controls from the general population, producing a comparison group of 178,821 people. The researchers also identified 26,000 IBD-free full siblings of the patients and ran a parallel analysis comparing patients directly against their own brothers and sisters.

That sibling comparison is what separates this study from the large body of prior research on IBD and mental health. Full siblings share approximately half their genetic material and typically grow up in the same household, meaning differences between them cannot be explained by shared family genetics, childhood environment, or socioeconomic background. Whatever drove the psychiatric risk difference had to be something specific to the IBD patients themselves.

When the researchers mapped psychiatric risk across time, starting five years before IBD diagnosis and extending ten years after, a pattern emerged that nobody had looked for before.

The elevated psychiatric risk did not begin at diagnosis. It began two to three years earlier.

What the timeline actually looks like

The hazard ratio for developing any psychiatric disorder started rising measurably around two to three years before a patient received their IBD diagnosis. By two years before diagnosis, IBD patients were already 15% more likely to develop a psychiatric disorder than matched controls. The gap continued widening as diagnosis approached.

Within the first six months after diagnosis, the risk peaked at 50% higher than controls. This is the moment most clinical attention has focused on, and it is real. But framing it as a post-diagnosis phenomenon, as prior research has consistently done, misses the years of accumulating psychiatric risk that came before.

After that six-month peak, the relative risk declined but did not return to baseline. A decade after diagnosis, IBD patients were still 19% more likely to have developed a psychiatric disorder than age-matched controls.

The sibling analysis confirmed the pattern held even when controlling for everything shared family members have in common. “Similar risk increases for psychiatric disorders were observed in the sibling-controlled cohort,” the researchers reported, ruling out the possibility that shared genetics or family environment explained the association.

Prescriptions for psychiatric medications, specifically antidepressants and anxiolytics, showed a similar trajectory. They began increasing in IBD patients a full year before gut diagnosis and remained elevated for at least five years afterward.

“It is time to actively manage psychiatric conditions in patients with IBD,” said lead author Jiangwei Sun of the Karolinska Institute in Sweden.

What is driving the pre-diagnosis psychiatric risk

The finding that psychiatric risk rises before IBD is even identified points toward biological mechanisms rather than the psychological burden of illness. Two pathways are under active investigation.

The first is subclinical gut inflammation. IBD does not appear suddenly. The inflammatory processes that eventually produce visible gut damage can be present and active for months or years before symptoms become severe enough to trigger a medical evaluation and formal diagnosis. During that subclinical period, the gut-brain axis, the bidirectional communication network linking the gastrointestinal tract to the central nervous system through the vagus nerve, immune signaling, and the microbiome, may already be transmitting disrupted signals to the brain.

The gut produces roughly 90% of the body’s serotonin, and gut inflammation alters how that serotonin is synthesized, released, and regulated. Systemic inflammation driven by early IBD activity also crosses into the brain through inflammatory cytokines, which are small proteins that influence mood, cognition, and stress response. Both pathways could plausibly generate the anxiety and depression that appear in the data years before a gastroenterologist makes a diagnosis.

The second pathway is the stress of unexplained chronic physical symptoms. IBD patients typically experience months or years of abdominal pain, urgency, fatigue, and digestive disruption before they receive a diagnosis. Living with severe, undiagnosed physical symptoms that disrupt daily functioning and cannot be explained is itself a significant source of psychological distress. The psychiatric signal in the pre-diagnosis years may partly reflect this diagnostic odyssey rather than purely biological gut-brain crosstalk, though the sibling comparison makes a pure psychosocial explanation unlikely to tell the whole story.

Which psychiatric conditions were most affected

The elevated psychiatric risk was primarily driven by three categories of disorder: major depressive disorder, anxiety disorders, and substance misuse. These accounted for most of the excess psychiatric burden observed across the study period.

The study found no significant increase in psychotic disorders or personality disorders in IBD patients, and no increase in ADHD. Autism spectrum disorders were more common in IBD patients in the period shortly after diagnosis. Eating disorders showed an elevated association from five or more years after diagnosis onward, a finding that deserves further investigation given the dietary restrictions and food-related anxiety common in IBD management.

The risk patterns were consistent across all three major subtypes of IBD: Crohn’s disease, ulcerative colitis, and IBD-unclassified. No single subtype drove the results.

Two groups showed particularly high absolute risks of psychiatric comorbidity. Patients with childhood-onset IBD carried the highest burden, a finding consistent with prior research showing that adolescent onset of chronic illness disrupts psychological development in ways that adult-onset illness does not. Patients with a family history of psychiatric conditions also showed elevated absolute risk, though the relative risk pattern over time was similar to the broader cohort.

What this means for clinical care

The clinical implications follow directly from the timeline. If psychiatric risk begins rising two to three years before IBD diagnosis, screening and intervention cannot wait until after a patient receives a gut diagnosis. By the time the gastroenterologist sees the patient, the psychiatric vulnerability has been building for years.

The researchers recommend that mental health screening begin during initial gastroenterology evaluation, the first point at which patients enter the GI care system. They also advocate for integrating psychological care directly into routine IBD management rather than treating it as a secondary concern that patients should address separately with a different specialist.

This is a significant shift from current practice, in which mental health support for IBD patients is often reactive rather than systematic. Patients are typically referred to psychological care after they report symptoms, rather than being screened proactively as part of IBD management from the beginning.

The drug prescription data adds urgency. Antidepressant and anxiolytic prescriptions in IBD patients were elevated a year before gut diagnosis and remained elevated for at least five years after. This means many patients were already receiving psychiatric medication before anyone connected their mental health to their gut condition. Better integration of gastroenterological and psychiatric care could change both the timing and the quality of mental health support these patients receive.

The limits of what the study can establish

The study is observational and relies on registry data, which means it can document associations and timing but cannot establish precise causal mechanisms. The IBD population was drawn from Swedish national registries, and while Sweden’s universal healthcare system produces unusually complete medical records, the findings may not generalize identically to populations with different healthcare access or different IBD prevalence rates.

The sibling comparison, while methodologically strong, does not rule out differences between siblings beyond their IBD status. A sibling who develops IBD may have experienced different life events, dietary patterns, or environmental exposures even within a shared household, and those differences could contribute to the psychiatric risk gap.

The study also does not distinguish between patients who had subclinical gut inflammation for years before diagnosis and those who had rapid-onset IBD with a shorter pre-diagnostic period. Separating those trajectories could clarify how much of the pre-diagnosis psychiatric signal is driven by biological gut-brain disruption versus the stress of undiagnosed physical illness.

What the study establishes with unusual confidence, across 43,000 patients, 178,000 controls, and 26,000 sibling comparisons, is the timeline itself. The mental health crisis in IBD begins before the diagnosis does. That fact alone requires a rethinking of when and how psychiatric care enters the picture for these patients.

The study “Psychiatric disorders before and after inflammatory bowel disease diagnosis: a nationwide cohort study in Sweden 2007 to 2023” was authored by Jiangwei Sun, Lin Li, Zheng Chang, Agnieszka Butwicka, David Bergman, Shihua Sun, Carole A. Marxer, Jonas Halfvarson, Ola Olen, and Jonas F. Ludvigsson at the Karolinska Institute and collaborating institutions, and published in Clinical Gastroenterology and Hepatology.

Source: Karolinska Institute / American Gastroenterological Association. DOI: 10.1016/j.cgh.2026.05.034